Vaxxinity, Inc. (NASDAQ: VAXX) is a clinical-stage biotechnology company headquartered in Dallas, Texas, pioneering synthetic peptide vaccines for chronic diseases, including Alzheimer's disease, Parkinson's disease, and other protein aggregation disorders[1]. The company's mission is to democratize antibody therapeutics through vaccination, offering a cost-effective alternative to passive antibody administration.
| Attribute | Details |
|---|---|
| Ticker | NASDAQ: VAXX |
| Founded | 2014 |
| Headquarters | Dallas, Texas, USA |
| CEO | Mei Mei Hu |
| Market Cap | ~$50-75 million (2024) |
| Employees | ~50 |
| Sector | Biotechnology |
Vaxxinity was founded in 2014 with the goal of developing vaccines that could induce therapeutic antibody responses against disease-specific protein targets. The company went public in 2021, raising approximately 0 million in its IPO[1:1].
Vaxxinity's proprietary platform uses synthetic peptide immunogens to induce broad, high-titer antibody responses against specific protein targets. Key features include:
| Advantage | Description |
|---|---|
| Cost | Single series vs. repeated antibody infusions |
| Accessibility | Can be administered in standard healthcare settings |
| Compliance | No need for regular hospital visits |
| Durability | Single vaccination may provide multi-year protection |
| Breadth | Can target multiple epitopes simultaneously |
UB-311 is Vaxxinity's lead program and the first anti-amyloid vaccine to reach Phase 2 clinical testing[2].
| Attribute | Details |
|---|---|
| Target | Amyloid-beta (Aβ) aggregates |
| Mechanism | Active vaccination inducing anti-Aβ antibodies |
| Route | Intramuscular injection |
| Phase | Phase 2 |
| Trial ID | NCT05462106 |
Phase 1 Study:
Phase 2 Study (NCT05462106):
UB-312 is the first alpha-synuclein vaccine to enter Phase 2 clinical testing[3].
| Attribute | Details |
|---|---|
| Target | Alpha-synuclein (α-syn) aggregates |
| Mechanism | Active vaccination inducing anti-α-syn antibodies |
| Route | Intramuscular injection |
| Phase | Phase 2 |
| Trial ID | NCT05669612 |
| Program | Target | Indication | Status |
|---|---|---|---|
| UB-313 | Tau | Alzheimer's/PSP | Preclinical |
| UB-400 | TDP-43 | ALS/FTD | Discovery |
Active vaccination against amyloid-beta has a complex history in Alzheimer's disease:
| Round | Year | Amount |
|---|---|---|
| Series A | 2015 | Undisclosed |
| Series B | 2018 | 0M |
| Series C | 2020 | 0M |
| IPO | 2021 | 0M |
| Post-IPO | 2022-2024 | At-the-market offerings |
| Company | Vaccine | Mechanism | Phase |
|---|---|---|---|
| Novartis/Cytos | CAD106 | Anti-Aβ peptide | Phase 2/3 |
| AC Immune/Genentech | ACI-35 | Anti-pTau liposome | Phase 1b |
| Vaxxinity | UB-311 | Anti-Aβ peptide | Phase 2 |
| Company | Vaccine | Mechanism | Phase |
|---|---|---|---|
| Vaxxinity | UB-312 | Anti-α-syn | Phase 2 |
| Prothena | PRX002 | Anti-α-syn antibody | Phase 1 |